|
|
|
| From NAFLD to MAFLD: Not just a change in the name |
| Jing Zeng a , Jian-Gao Fan a , b , ∗ |
a Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
b Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai 200092, China
∗ Corresponding author at: Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
E-mail address: fanjiangao@xinhuamed.com.cn (J.-G. Fan) . |
|
|
|
|
Abstract The names of many diseases have changed over time, and the criteria of successfully changing the name of a disease should make sense, be easy to say and write, get quick endorsement by professional societies, and keep the same acronym. In general, a change in the name of a disease usually represents an improvement in the understanding of the disease, whether on clinical settings and natural history or pathophysiological aspects. The successful renamed liver diseases in history include from non-A non-B hepatitis, non-B non-C hepatitis, primary biliary cirrhosis to hepatitis C, hepatitis E and primary biliary cholangitis, respectively. Therefore, the rename of the disease that is finally used usually clearly indicates its main characteristics.
|
|
|
|
|
|
| [1] |
Li JH, Xu X, Wang YF, Xie HY, Chen JY, Dong NG, Badiwala M, Xin LM, Ribeiro RVP, Yin H, Zhang H, Zhang JZ, Huo F, Yang JY, Yang HJ, Pan H, Li SG, Qiao YB, Luo J, Tang PF, Ye QF, Zheng SS. Chinese expert consensus on organ protection of transplantation (2022 edition)[J]. Hepatobiliary Pancreat Dis Int, 2022, 21(6): 516-526. |
|
|
|
|
2022, Vol. 21 
